Results 201 to 210 of about 3,049 (238)
Some of the next articles are maybe not open access.
Advances in LDL-apheresis for the treatment of severe hypercholesterolemia
Current Opinion in Lipidology, 1994LDL-apheresis is an extracorporeal plasma-perfusion method that selectively removes apolipoprotein B-containing lipoproteins from the blood. It is indicated for patients with homozygous and drug-resistant heterozygous familial hypercholesterolemia. Clinical and angiographic regression of coronary artery disease has been demonstrated in patients treated
Bruce R. Gordon, Stuart D. Saal
openaire +3 more sources
LDL apheresis as it relates to nursing practice
Transfusion and Apheresis Science, 2017Nurses are an essential partner in the treatment of complex diseases and they have extensive influence on patient outcomes. Connecting a patient to a machine takes courage, skill, and a whole lot of trust. Anyone who has earned the title of "nurse" has shown courage. Skill comes with hours and hours of practice. Trust is earned and ongoing.
openaire +3 more sources
Therapeutic Apheresis, 1996
Abstract: Guest Editor's Introduction: The binding site of the human LDL receptor is rich in anionic amino acids, and interacts with apolipoprotein‐B by the electrostatic force. Therefore, anionic ligands could be used for the selective adsorption of LDL without HDL adsorption. Based upon this concept, Kaneka Co. developed LDL adsorbent. The adsorbent
openaire +4 more sources
Abstract: Guest Editor's Introduction: The binding site of the human LDL receptor is rich in anionic amino acids, and interacts with apolipoprotein‐B by the electrostatic force. Therefore, anionic ligands could be used for the selective adsorption of LDL without HDL adsorption. Based upon this concept, Kaneka Co. developed LDL adsorbent. The adsorbent
openaire +4 more sources
LDL apheresis: current situation in Japan [PDF]
, 1990 LDL apheresis using dextran sulfate cellulose beads has been recognized as the best therapeutics for severe familial hypercholesterolemia. It was approved for commercial distribution by Japanese government in 1986. Since 1986, more than 15,000 treatments have been done on about 600 patients.
openaire +1 more source
[LDL-apheresis in the treatment of familial hypercholesterolemia].
La Ricerca in clinica e in laboratorio, 1985Several non-pharmacological treatments have been tested for homozygous familial hypercholesterolemia and, among these, plasma-exchange has been the most safe and effective. A recent development of this procedure is LDL-apheresis, that is the selective removal of atherogenic LDL and the return to the patient of his own LDL-depleted plasma. The method is
SCARPATO, NICOLA, POSTIGLIONE, ALFREDO
openaire +2 more sources
26 Years of LDL – Apheresis: A review of experience
Transfusion and Apheresis Science, 2009Since 1981, when LDL-Apheresis was introduced into the clinical routine at the University of Cologne as the first and so far only Apoprotein B specific LDL-cholesterol elimination technique, considerable experience has since then accumulated and has changed not only the operational technique but also extended the indications, the optimation of the ...
openaire +3 more sources
Treatment methods for LDL apheresis
Journal of Clinical Apheresis, 1994Andrea Bertrams +2 more
openaire +3 more sources
LDL APHERESIS AND REGRESSION OF ATHEROSCLEROSIS
The Lancet, 1985D. N. Mukhin +6 more
openaire +3 more sources
The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis
Therapeutic Apheresis and Dialysis, 2021Takaya Abe, Hui Jiang, Adrián Ramírez
exaly